Print

Immunomedics, Inc. (IMMU) Presents Epratuzumab's Mechanism of Action in Systemic Lupus Erythematosus  
6/13/2013 8:46:27 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MADRID, Spain, June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, mediates the reduction of select proteins on the surface of B cells via a process known as trogocytosis, and that such reduction could modulate B-cell activities.Results from this study were presented by Edmund A. Rossi, Ph.D., Executive Director, Recombinant Technology.

Help employers find you! Check out all the jobs and post your resume.

//-->